Irinotecan Aurobindo

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Aurobindo, is a topoisomerase I inhibitor presented as a sterile injectable formulation for intravenous use. It treats metastatic and advanced colorectal cancer in adult patients.

GNH USA supplies Irinotecan Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan Aurobindo is a chemotherapy agent that targets colorectal cancer pathways. - Metastatic colorectal cancer: improves overall survival when used in combination regimens. - Advanced colorectal cancer: reduces tumor progression and disease burden. - Colorectal adenocarcinoma: contributes to disease control as part of standard first‑line therapy.

Irinotecan may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Diarrhea: may be severe and require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment. - Fatigue: generalized tiredness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count. - Severe diarrhea leading to dehydration. - Intestinal perforation: rare but life‑threatening. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes. - Cardiac toxicity: rare arrhythmias or ischemia.

Before initiating therapy, several safety considerations are required. - Baseline blood counts: assess neutrophil and platelet levels. - Liver function: evaluate hepatic enzymes and bilirubin. - Renal function: monitor creatinine clearance. - Concomitant medications: review for agents that may increase toxicity. - Patient education: advise on signs of severe diarrhea and infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other drugs, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce SN‑38 exposure. - Anticholinergic agents: can exacerbate constipation and ileus.

Moderate Interactions (Monitor Closely): - UGT1A1 inhibitors (e.g., atazanavir): may increase SN‑38 levels. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other myelosuppressive chemotherapy: additive bone‑marrow suppression. - Diuretics: risk of electrolyte imbalance with diarrhea.